ArticleNature communications2026
Surface hydrophobicity and rigidity determines protein corona on orally delivered nanoparticles treating colitis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Increasing hydrophobicity in poly(amino acid) adjuvants elicits potent and durable anti-tumor immunityBioactive materials · 2027Article
- Review
- Advances in Living Cell-Mediated Nanodrug Delivery Systems: Construction Strategies, Applications and Challenges.Pharmaceutics · 2026Review
- Mechanical insights into regulation of bio-nano interactions for lipid-based nanocarriers.Discover nano · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disease-specific protein corona adsorbed on nanocarriers determines in vivo delivery efficiency. Macrophages can orchestrate inflammation resolution and mucosa repair, making them a promising therapeutic target in colitis. Here, we show that surface hydrophobicity and rigidity determine colitis-specific intestinal protein corona (C-IPC) on orally delivered nanoparticles for treating colitis, which improves therapeutic efficiency. We show that high surface hydrophobicity boosts overall protein adsorption, leading to improved colon macrophage delivery and therapeutic effect when loaded with budesonide. Moreover, hydrophobicity with high rigidity results in a corona enriched with macrophage-targeting proteins, notably S100A8, generating an optimal C-IPC characterized by both high protein amount and high proportion of targeting proteins. Consequently, high rigidity nanoparticles more effectively attenuates the inflammatory state and restores the immune homeostasis in male rats with colitis. Our work develops a rational strategy of manipulating protein corona formation through physicochemical properties for efficient oral drug delivery, holding broad promise for diverse nanocarriers and pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.